AC Immune SA's Phase 2b study for Alzheimer’s drug ACI-35.030 has temporarily paused enrollment for evaluation, but this does not impact their liquidity position and is unrelated to safety findings. They anticipate reporting additional clinical results throughout 2026, and expect to meet operating requirements until Q3 2027.